Cara Therapeutics to Host Virtual Research and Development Event on April 7, 2021
March 31 2021 - 7:00AM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus by selectively targeting peripheral
kappa opioid receptors, or KORs, today announced that the Company
will host a virtual research and development (R&D) event on
April 7 from 1:00 p.m. to 3:00 p.m. ET. The virtual event will
include a presentation and interactive Q&A session to explore
Cara’s first-in-class KOR agonist, KORSUVA™ (difelikefalin), being
investigated for the treatment of chronic pruritus in systemic,
dermatological, and neurological indications.
In addition to Cara’s management team, featured
guest presenters will include:
Brian Kim, M.D., MTR,
FAAD, Associate Professor of Medicine, Anesthesiology, and
Pathology and Immunology; Co-Director of the Center for the Study
of Itch and Sensory Disorders, Division of Dermatology, Department
of Medicine at Washington University School of Medicine, MO
Mark Lebwohl, M.D.,
Professor and Dean for Clinical Therapeutics, Chairman Emeritus,
Kimberly and Eric J. Waldman Department of Dermatology at the Icahn
School of Medicine at Mount Sinai, NY
Virtual Event Details:
A live audio webcast of the presentation with
accompanying slides will be accessible under "Events &
Presentations" in the News & Investors section of the Company's
website at www.CaraTherapeutics.com. A replay of the webcast
will be archived on the Company's website following the
presentation.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body’s peripheral nervous system, as well as
certain immune cells. In two Phase 3 trials, KORSUVA Injection has
demonstrated statistically significant reductions in itch intensity
and concomitant improvement in quality of life measures in
hemodialysis patients with moderate-to-severe chronic kidney
disease-associated pruritus (CKD-aP). The U.S. Food and Drug
Administration (FDA) has accepted and granted Priority Review for
the New Drug Application (NDA) for KORSUVA™ (difelikefalin)
solution for injection for the treatment of moderate-to-severe
pruritus in hemodialysis patients. The PDUFA target action date for
KORSUVA is August 23, 2021. Oral KORSUVA™ has successfully
completed a Phase 2 trial for the treatment of pruritus in patients
with CKD and is currently in Phase 2 trials in atopic dermatitis,
primary biliary cholangitis and notalgia paresthetica patients with
moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA™ as the trade name
for difelikefalin solution for injection. Difelikefalin is an
investigational drug product and its safety and efficacy have not
been fully evaluated by any regulatory authority.
Forward-looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Examples of these
forward-looking statements include statements concerning the
potential regulatory approval of KORSUVA™ solution for injection
and the potential timeline for FDA review of the NDA and the
potential of KORSUVA™ to be a therapeutic option for CKD-aP or
pruritus in other systemic, dermatological, and/or neurological
indications. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Risks are
described more fully in Cara's filings with the Securities and
Exchange Commission, including the "Risk Factors" section of Cara's
Annual Report on Form 10-K for the year ended December 31, 2020 and
its other documents subsequently filed with or furnished to the
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Except to the extent required by law, Cara
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
MEDIA CONTACT: Claire LaCagnina6
Degrees315-765-1462 clacagnina@6degreespr.com
INVESTOR CONTACT:Janhavi MohiteStern Investor
Relations, Inc.janhavi.mohite@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024